BR112012033284A2 - veículo vacinal para induzir resposta imune celular, composição vacinal, e, uso da composição vacinal - Google Patents

veículo vacinal para induzir resposta imune celular, composição vacinal, e, uso da composição vacinal

Info

Publication number
BR112012033284A2
BR112012033284A2 BR112012033284A BR112012033284A BR112012033284A2 BR 112012033284 A2 BR112012033284 A2 BR 112012033284A2 BR 112012033284 A BR112012033284 A BR 112012033284A BR 112012033284 A BR112012033284 A BR 112012033284A BR 112012033284 A2 BR112012033284 A2 BR 112012033284A2
Authority
BR
Brazil
Prior art keywords
vaccine
immune response
vaccine composition
vehicle
composition
Prior art date
Application number
BR112012033284A
Other languages
English (en)
Other versions
BR112012033284B1 (pt
Inventor
Valle Garay Aisel
Manuel Alvarez Valcárcel Carlos
Mesa Pardillo Circe
Fabíola Pazos Santos Isabel
Canet Santos Liem
Enrique Fernándes Molina Luis
Eliana Lanio Ruiz Maria
Eugenia Alonso Biosca Maria
Del Carmen Luzardo Lorenzo Maria
Tejuca Martinez Mayra
Judith Laborde Quintana Rady
Cruz Leal Yoelys
Original Assignee
Centro De Immunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44533576&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012033284(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centro De Immunologia Molecular filed Critical Centro De Immunologia Molecular
Publication of BR112012033284A2 publication Critical patent/BR112012033284A2/pt
Publication of BR112012033284B1 publication Critical patent/BR112012033284B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

veículo vacinal para induzir resposta imune celular, composição vacinal, e, uso da composição vacinal. a presente invenção diz respeito ao campo da biotecnologia aplicada à saúde humana. a invenção descreve um veículo de vacina, em que as toxinas de organismos eucariótivos são encapsuladas em lipossomos com múltiplas camadas lipídicas, obtidas por meio do processo de desidratação/reidratação, cuja composição lipídica é dipalmitoifosfatidilcolina : colesterol em uma razão molar de 1;1, as quais são determinadas para administração subcutânea ou intramuscular. estas composições não exigem o uso de outros adjuvantes. as composições descritas permitem a modulação da resposta imune ctl específica para um ou mais antígenos coencapsulados nos lipossomos que contêm a toxina. o veículo da vacina da presente invenção apresenta vantagens quando comparadas a outros descritos na técnica anterior, devido à natureza forte e funcional da resposta imune induzida e também às propriedades de imunomodução destes.
BR112012033284-8A 2010-07-06 2011-07-05 veículo vacinal para induzir resposta imune celular, e, composição vacinal BR112012033284B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU20100144A CU20100144A7 (es) 2010-07-06 2010-07-06 Composiciones vacunales a base de sticholisina encapsulada en liposomas
CUCU/P/2010/144 2010-07-06
PCT/CU2011/000004 WO2012003814A1 (es) 2010-07-06 2011-07-05 Composiciones vacunales a base de sticholisina encapsulada en liposomas

Publications (2)

Publication Number Publication Date
BR112012033284A2 true BR112012033284A2 (pt) 2017-05-02
BR112012033284B1 BR112012033284B1 (pt) 2021-05-18

Family

ID=44533576

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012033284-8A BR112012033284B1 (pt) 2010-07-06 2011-07-05 veículo vacinal para induzir resposta imune celular, e, composição vacinal

Country Status (24)

Country Link
US (1) US8697093B2 (pt)
EP (1) EP2591802B1 (pt)
JP (1) JP5685646B2 (pt)
KR (1) KR101455055B1 (pt)
CN (1) CN102971011B (pt)
AR (1) AR081661A1 (pt)
AU (1) AU2011276812B2 (pt)
BR (1) BR112012033284B1 (pt)
CA (1) CA2802443C (pt)
CL (1) CL2012003674A1 (pt)
CO (1) CO6640312A2 (pt)
CU (1) CU20100144A7 (pt)
EA (1) EA025333B1 (pt)
ES (1) ES2576851T3 (pt)
HK (1) HK1177138A1 (pt)
MX (1) MX2012015173A (pt)
MY (1) MY167896A (pt)
PE (1) PE20130390A1 (pt)
SG (1) SG186931A1 (pt)
TN (1) TN2012000592A1 (pt)
TW (1) TWI457145B (pt)
UA (1) UA111944C2 (pt)
WO (1) WO2012003814A1 (pt)
ZA (1) ZA201300059B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6238366B2 (ja) * 2012-08-28 2017-11-29 国立大学法人北海道大学 非極性溶媒に分散性を有する細菌菌体成分を内封する脂質膜構造体およびその製造方法
KR102069670B1 (ko) * 2017-03-02 2020-01-23 단디바이오사이언스 주식회사 면역활성물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물
EP3651733A4 (en) * 2017-07-10 2021-04-07 ImmunoVaccine Technologies Inc. PHARMACEUTICAL COMPOSITIONS, METHOD OF MANUFACTURING USING LIPID VESICLE PARTICLES OF DEFINED SIZE, AND USES THEREOF
CN113041346A (zh) * 2019-12-26 2021-06-29 复旦大学 一种细菌毒素疫苗及其在预防细菌感染中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2135406T3 (es) 1991-05-08 1999-11-01 Schweiz Serum & Impfinst Virosomas de la influenza reconstituidos inmunoestimulantes e inmunopotencializadores y vacunas que los contienen.
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
EP1797895A1 (en) 2005-12-16 2007-06-20 Pevion Biotech Ltd. An adjuvant system comprising virosomes and liposomes
AU2006351536B2 (en) 2006-12-04 2011-11-24 National Agriculture And Food Research Organization Method for producing biomineral-containing substance and organic hydroponics method

Also Published As

Publication number Publication date
ZA201300059B (en) 2013-09-25
CA2802443A1 (en) 2012-01-12
ES2576851T3 (es) 2016-07-11
TW201217000A (en) 2012-05-01
EP2591802A1 (en) 2013-05-15
SG186931A1 (en) 2013-02-28
AR081661A1 (es) 2012-10-10
EA025333B1 (ru) 2016-12-30
TN2012000592A1 (en) 2014-04-01
AU2011276812A1 (en) 2013-01-10
CU20100144A7 (es) 2012-06-21
JP5685646B2 (ja) 2015-03-18
AU2011276812B2 (en) 2013-12-19
WO2012003814A1 (es) 2012-01-12
KR20130027547A (ko) 2013-03-15
CO6640312A2 (es) 2013-03-22
BR112012033284B1 (pt) 2021-05-18
CN102971011A (zh) 2013-03-13
US20130149376A1 (en) 2013-06-13
EP2591802B1 (en) 2016-06-08
EA201291449A1 (ru) 2013-05-30
KR101455055B1 (ko) 2014-10-28
CA2802443C (en) 2015-03-17
CN102971011B (zh) 2014-12-03
MY167896A (en) 2018-09-26
UA111944C2 (uk) 2016-07-11
CL2012003674A1 (es) 2013-07-12
US8697093B2 (en) 2014-04-15
TWI457145B (zh) 2014-10-21
PE20130390A1 (es) 2013-04-11
JP2013530190A (ja) 2013-07-25
MX2012015173A (es) 2013-02-11
HK1177138A1 (en) 2013-08-16

Similar Documents

Publication Publication Date Title
BR112018000632A2 (pt) moléculas de anticorpo que ligam a cd79
BR112015017548A8 (pt) construção de anticorpo multiespecífico isolado, sequência de ácido nucléico, vetor, célula hospedeira, processo para a produção da construção de anticorpo, composição farmaceutica, uso da construção de anticorpo e kit
BR112013022397A2 (pt) vacinas combinadas com doses menores de antígeno e/ou adjuvante
EA035991B9 (ru) Новый полисахарид и его применения
BR112018000601A2 (pt) moléculas de anticorpo que se ligam ao cd22
CO6751288A2 (es) Composición antigénica de micobacteria
DOP2013000029A (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
CY1116811T1 (el) Λιποσωμα ιρινοτεκανης ή του υδροχλωριδιου αυτης και μεθοδος παρασκευης αυτου
BR112012027055A8 (pt) agente estabilizante para proteínas farmacêuticas.
BR112015017307A2 (pt) composições de espécies com baixa acidez e métodos para produção e uso das mesmas
BR112014031689A2 (pt) anticorpos reativos cruzados anti-jagged 1/jagged 2, anticorpos anti-jagged ativáveis e métodos de uso deles
BR112016006122A2 (pt) composições imunogênicas e métodos com coronavírus da síndrome respiratória do oriente médio (mers-cov)
BR112015000585A2 (pt) cepas mutantes de mycoplasma hyopneumoniae
BR112012032979A2 (pt) composição para limpeza límpida, de baixa irritação, e com ph relativamente baixo
BR112014008694A2 (pt) moléculas de ácido nucleico policistrônico recombinante
BR112015001390A2 (pt) vacina de proteína de fusão multimérica e imunoterápicos
BR112012030616A2 (pt) concentração de antígenos de vacina com liofilização.
BRPI0700148A (pt) emulsões cosméticas de baixa viscosidade e estabilidade prolongada, de preparação a frio
BR112015004875A2 (pt) formulações de anticorpo e seus usos
ES2663872T3 (es) Composición inmunogénica o vacuna contra infección o enfermedad bacteriana gramnegativa, por ejemplo, por Neisseria
BR112012033284A2 (pt) veículo vacinal para induzir resposta imune celular, composição vacinal, e, uso da composição vacinal
AR092372A1 (es) Formulaciones de liposomas, uso y metodo de tratamiento
BR112012028893A2 (pt) composições imunoestimuladoras e de vacina
BR112013029417A2 (pt) composições de vacina de matriz proteica incluindo policátions
BR112012028711A2 (pt) métodos para a fabricação de uma emulsão de óleo em água, para a preparação de um kit de vacina e para redestilação de uma composição compreendendo 99% de esqualeno ou mais, assim como emulsão de óleo em água e kit

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/07/2011, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 12A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2730 DE 02-05-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.